Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (NASDAQ: ACIU) generates frequent news flow as a clinical-stage biopharmaceutical company developing precision therapeutics and diagnostics for neurodegenerative diseases. Company updates often center on clinical trial progress for its active immunotherapies and small-molecule programs targeting misfolded proteins implicated in Alzheimer’s disease, Parkinson’s disease and other NeuroOrphan indications.
Investors following ACIU news can expect detailed reports on interim and top-line data from key studies, such as the Phase 2 VacSYn trial of ACI-7104.056 in early Parkinson’s disease and the Phase 2 ABATE and ReTain trials in Alzheimer’s disease. Recent releases have highlighted strong immunogenicity and favorable safety for ACI-7104.056, biomarker trends suggesting potential stabilization of Parkinson’s disease pathology, and peer-reviewed results for the Tau-targeting active immunotherapy ACI-35.030 published in eBioMedicine.
News items also cover AC Immune’s diagnostic imaging efforts, including preclinical and clinical updates on PET tracers like ACI-19626 for TDP-43 pathology, with data published in Nature Communications. Corporate communications frequently include quarterly financial results, cash runway disclosures, pipeline prioritization decisions, workforce adjustments, and information on collaborations with partners such as Janssen, Takeda and Lilly.
This ACIU news page aggregates these company-issued announcements and regulatory communications, giving readers a single place to review clinical milestones, scientific publications, conference presentations and strategic corporate actions. For those tracking AC Immune’s progress in precision prevention of neurodegenerative diseases, it provides an organized view of how the pipeline and partnerships are evolving over time.
AC Immune SA (NASDAQ: ACIU) has announced its participation in the Alzheimer’s Association International Conference (AAIC) from July 31 to August 4, 2022, in San Diego. The company will present 10 findings, including new Phase 2 results for the Tau PET tracer PI-2620 and an innovative clinical trial design for ACI-24.060 aimed at Alzheimer's and Down syndrome patients. CEO Andrea Pfeifer emphasized the significance of these results in shifting treatment paradigms for neurodegenerative diseases, highlighting the collaboration with partners like Genentech.
AC Immune SA (NASDAQ: ACIU) held its Annual General Meeting in June 2022, where shareholders re-elected the Board of Directors. Douglas Williams continues as Chairman. The company reported progress in its pipeline, including interim Phase 1b/2a data for the anti-pTau vaccine ACI-35.030 and clinical proof-of-concept for an alpha-synuclein PET tracer. They remain on track for four additional clinical data readouts in 2022 and have sufficient cash for operations into 2024.
AC Immune SA (NASDAQ: ACIU) announced results from its Alzheimer’s Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial. The investigational drug, crenezumab, did not statistically significantly slow cognitive decline in patients with a specific genetic mutation linked to early-onset Alzheimer’s. Although numerical advantages over placebo were noted, they lack statistical significance. The trial, involving 252 participants, reported no new safety issues. Initial data will be shared at the Alzheimer's Association International Conference on August 2, 2022.
AC Immune announced participation in the 2022 Jefferies Healthcare Conference from June 8-10, 2022, in New York. CEO Andrea Pfeifer will discuss the company's progress in neurodegenerative disease treatments during a fireside chat on June 9 at 8:00 am EDT. The company aims to shift the treatment paradigm towards early diagnosis and disease prevention. Key milestones include the reporting of Phase 2 results for crenezumab in an Alzheimer's prevention trial, expected soon. AC Immune is focused on advancing precision medicine through its innovative therapeutic and diagnostic pipeline.
AC Immune (NASDAQ: ACIU) announced that CEO Dr. Andrea Pfeifer will receive the Aenne Burda Award for Creative Leadership during the DLD Conference in Munich, May 20-22, 2022. This award recognizes her pioneering work in neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Under her leadership since 2003, AC Immune has developed a promising pipeline of diagnostics and treatments, positioning the company as a leader in precision medicine. The award highlights the urgency of addressing global challenges posed by these diseases.
AC Immune SA (NASDAQ: ACIU) has published findings in JAMA Neurology demonstrating the safety and immunogenicity of its ACI-24 anti-Abeta vaccine in individuals with Down syndrome (DS). This Phase 1b trial showed a positive immune response without serious adverse effects, indicating the vaccine's potential for future Alzheimer’s disease interventions. An optimized formulation is set to enter further clinical testing this year, reinforcing AC Immune's commitment to addressing neurodegenerative diseases.
AC Immune, a clinical-stage biopharmaceutical company, reported Q1 2022 results highlighting key advancements in neurodegenerative disease treatments. They announced favorable interim data from the ACI-35.030 anti-pTau vaccine, showcasing strong immunogenicity and safety. Additionally, the ACI-12589 PET tracer provided first images of alpha-synuclein in human brains, critical for diagnosing MSA. With a solid cash position of CHF 173.8 million, the company remains funded through at least Q1 2024, expecting five more clinical readouts by year's end to boost value creation.
AC Immune SA (NASDAQ: ACIU) announced its participation in the B.Riley Annual Neuro & Ophthalmology Virtual Investor Conference on April 27-28, 2022. CEO Prof. Andrea Pfeifer will host a Fireside chat on April 28 at 11:30 am EDT, discussing the company's development pipeline for neurodegenerative diseases and upcoming clinical milestones. Having achieved two milestones in Q1, AC Immune will present five more data readouts this year, highlighting its precision medicine approach. The webcast will be available on the company's website.
AC Immune SA (NASDAQ: ACIU) announces significant management changes, appointing Howard Donovan as Chief HR Officer and promoting Chris Roberts to Interim CFO, due to Joerg Hornstein's departure. Donovan brings extensive HR experience from the World Economic Forum, while Roberts has a strong finance background, essential for AC Immune's financial operations. Julian Snow is also promoted to Vice President, U.S. Finance & Corporate Development. The changes aim to strengthen the company's internal functions as it continues to develop precision medicine for neurodegenerative diseases.
AC Immune SA (NASDAQ: ACIU) announced the clinical validation of its a-syn PET tracer, ACI-12589, which distinguishes multiple system atrophy (MSA) from other a-synucleinopathies. This groundbreaking development, presented by Dr. Oskar Hansson, shows ACI-12589's potential in enabling targeted therapeutics and diagnostics for neurodegenerative diseases. With two validated technology platforms and a robust pipeline, AC Immune aims to accelerate therapeutic development. The company expects seven clinical data readouts in 2022, highlighting its commitment to precision medicine.